Information Provided By: 
Fly News Breaks for September 6, 2019
PRAH
Sep 6, 2019 | 08:46 EDT
Jefferies analyst David Windley raised his price target for PRA Health Science to $120 from $115 saying he continues to view the company as the best near-term contract research origination long opportunity. The revenue guidance reset in Q2 "removed an impediment for potential buyers," Windley tells investors in a research note. He believes PRA's revenue should still accelerate to ~10% growth exiting 2019 and continue in 2020. The analyst keeps a Buy rating on the shares.
News For PRAH From the Last 2 Days
There are no results for your query PRAH
